Reactions 1680, p331 - 2 Dec 2017 Acantholytic dyskeratotic acanthoma: case report A 62-year-old woman developed acantholytic dyskeratotic acanthoma (ADA) following the therapy with vemurafenib. The woman was diagnosed with melanoma when she was 59 years old. She had undergone surgery, followed by nivolumab therapy. However, the disease progressed and advanced to systemic metastasis. Hence, to treat the multiple metastasis, she started receiving therapy with vemurafenib 960 mg/day [route not stated]. After one month of vemurafenib initiation, she developed a keratotic papule on her right shoulder. A skin biopsy of the papule was performed, which ruled out the possibility of squamous cell carcinoma. Histologically, the lesion demonstrated mild papillomatous acanthosis and hyperkeratosis. Acantholysis and dyskeratosis with corp ronds and grains were noted. Therefore, the papule was diagnosed as ADA that developed due to the vemurafenib therapy [outcome not stated]. Author comment: "In conclusion, we experienced a case of vemurafenib-induced ADA." Komori T, et al. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment. Journal of the European Academy of Dermatology and Venereology 31: e474-e475, No. 10, Oct 2017. Available from: URL: http:// doi.org/10.1111/jdv.14289 - Japan 803284154 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera